Colonoscopy is the gold standard for detecting colon cancer, but every year about 50 million people in the U.S. who qualify for a colonoscopy don't get it done, according to the American Cancer ...

Shield’s FDA-approved blood test drives cancer screening growth, pricing power, and cash-flow upside. Click for this GH ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

Co-CEO Helmy Eltoukhy highlighted record revenue of $202 million in Q4 2024, driven by 30% year-over-year growth, with total ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...

Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...

Screening for the second leading cause of cancer deaths just got a bit easier. The U.S. Food and Drug Administration (FDA) announced the approval of a new blood test for colorectal cancer (CRC).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...

A groundbreaking blood test for colorectal cancer screening has received approval from the U.S. Food and Drug Administration (FDA), offering the potential to revolutionize early detection for one of ...